Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Rizap Offering: Some Colour on This Fad-Nomenon and Mio's Diet and Health Advice You Never Wanted

MTG IPO Preview II: Powered By Celebrities

MTG: Strong Open, Bullish Market, but Valuations Make Us Inclined to Look for Exit Point

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p>The Sapporo Securities Exchange Ambitious board-listed Rizap Group is raising USD315 million in a placement to grow its business as well as pay down debt. With a market capitalization of only USD4.2 billion, the company is less known names with no analyst coverage according to Bloomberg screen. Having said that, it has interesting business lines on self-improvement of health and happiness with a track record of rapid growth, as well as re-rating potential for its subsidiary. We will also score the deal in our ECM framework.</p>

The Sapporo Securities Exchange Ambitious board-listed Rizap Group is raising USD315 million in a placement to grow its business as well as pay down debt. With a market capitalization of only USD4.2 billion, the company is less known names with no analyst coverage according to Bloomberg screen. Having said that, it has interesting business lines on self-improvement of health and happiness with a track record of rapid growth, as well as re-rating potential for its subsidiary. We will also score the deal in our ECM framework.

Rizap Group Placement: A Less Known Name With Sales to Double in Three Years